We wish to extend our sincere condolences to the families of those who lost their lives due to the COVID-19 coronavirus disease. We also express our heartfelt sympathy to everyone who has contracted the disease and hope for their early recovery.
Moreover, we convey our deepest gratitude to the medical health experts who are battling the coronavirus, and to the many essential workers in production, transportation and the sale of daily essentials, among other areas.
The MTI Group has since mid-March largely made the transition to a teleworking system to enable employees to work from home. It has also had a teleworking standardization system in place since October.
We are making every effort to prevent the spread of COVID-19, giving first priority to the safety and health of employees and all other stakeholders. We truly hope that the spread of the coronavirus disease will be contained at the earliest possible stage.

We are focusing on consecutively
healthcare-related service business.

~The number of paying subscribers has stopped declining.
And the sales of “Cloud drug record service” has been increasing~

 In the Group’s business environment during the current fiscal year, subscriptions from smartphone-based paying subscribers remained sluggish, mainly reflecting the requirement for large mobile phone carriers to separate communication charges and mobile device prices and the reduced business hours of mobile phone retailers across Japan in an effort to prevent the spread of the novel coronavirus (COVID-19). Meanwhile, demand for digital content increased as part of the stay-at-home order issued to prevent the spread of COVID-19 infection.

 The Company will focus on raising sales in the (new) healthcare business. In the content business, it will work to maintain the total number of paying subscribers as much as possible by promoting paid subscription to the security-related apps, and grow the original comic distribution business along with the outlook that the total number of paying subscribers will continue to decrease.
 The (new) healthcare business, in which the Company is engaged with a medium-term perspective, has strong growth potential in the long term and may move toward a stock type business with the provision of long-term support according to customers’ life stages. Accordingly, the Company is committed to implementing a variety of measures to achieve sales growth.In particular, the appetite for introducing a cloud drug record service has been growing for some time due to the Revision of the Medical Fee System. Because these factors contribute to continued sales growth of the (new) healthcare business, the Company plans to actively promote sales in cooperation with its partner, Medipal Holdings Corporation.
 The Company is providing online medical examinations and online medication advice, for which demand has been rising amid the COVID-19 pandemic, currently free of charge. By shifting these to paid services and encouraging their use, the Company will make the services contribute to medium-term profit growth.

 While the impact of the COVID-19 pandemic on the Company’s consolidated performance is expected to be negligible, the Company will promptly release any information requiring disclosure.

We hope that we can continue to count on your support as we pursue our initiatives.

November, 2020
President and Chief Executive Officer

代表取締役社長 前多俊宏